SUMMARY It has been suggested that polymer coating might retard jejunal absorption of 5-amino salicylic acid (5-ASA) and thus promote delivery to its colonic site of action. Twenty three patients with active (nine), or quiescent (14) ulcerative colitis were given either uncoated or coated 5-ASA (Asacol) 400 mg qds for one to three weeks, after which they ingested five 1-5 ml dialysis membrane sachets which were recovered from the stool in the next 72 hours. After one week of treatment the concentration of 5-ASA in the faecal dialysate, urine, and fasting plasma in those receiving the coated and uncoated preparations were respectively: 25-4±5*1 compared with 1-2±0*4 mmol/l (p<0001); 0.34±0-21 compared with 0-70±0-29 mmol/24h (NS) and 11.1±4.2 compared with 0-07±0-03 [imol/l (p<002). Faecal excretion of the drug appeared to be greater in patients with active colitis than in those with quiescent disease. Thus coating with pH dependent methacrylic acid copolymer B is a very effective method of promoting delivery of 5-ASA to the colon, stool dialysate concentrations being 20 fold more than those in controls. Increased trough plasma concentrations in the polymer coating group probably reflect delayed intestinal absorption but no evidence of plasma accumulation after 21 days of therapy was found.
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The use of sulphasalazine in the treatment of inflammatory bowel disease has been limited by side effects, mainly attributable to the sulphapyridine component.' 5-amino salicylic acid (5-ASA) is released in the colon by bacterial azoreduction of the parent molecule2 and 5-ASA is now known to be the active moiety."
Because of the adverse effects of sulphapyridine, recent work has been directed towards the development of systems which enable 5-ASA to be delivered to the colon without the concomitant administration of a sulphonamide. One method is to coat 5-ASA with a pH dependent polymer (Eudragit S) designed to disintegrate in the terminal ileum when the pH is consistently above 7.6 Such a preparation has been found to be effective for maintenance of a remission of ulcerative colitis7' and is well tolerated by most patients experiencing side effects of sulphasalazine."'2 Radiological studies have shown the integrity of polymer coated capsules in their passage to the colon6 but the value of the coating in promoting stool excretion of 5-ASA compared with the noncoated product, is unknown. The aim of the present study was to determine the serum concentrations, urinary and faecal excretion of 5-ASA after ingestion of a polymer coated preparation (Asacol) by patients with active and inactive ulcerative colitis, and to compare values with those obtained with a noncoated product. 7.4) which contained 0-075% (v/v) tetrabutylammonium hydroxide and was degassed by vacuum sonication. The flow rate was 1-8 ml/min. Analytes were detected fluorimetrically using a Perkins-Elmer model 3000 fluorescence spectrometer fitted with a 8 ,ul flow cell with a 2 mm pathlength. The excitation wavelength was 315 nm with a bandpass of 10 nm and the emission wavelength was 485 nm with a bandpass of 20 nm. The time constant was 2 seconds. Quantitation was achieved by peak area ratio measurements (analyte to internal standard) using a HewlettPackard integrator (model 3390A) and reference to calibration values obtained with a standard mixture made up in plasma (0-41-4-1 ,umol/l 5-ASA; 0-64-6-4 ismol/l acetyl 5-ASA).
Excellent separations of 5-ASA, DHBA and Acetyl 5-ASA were achieved (retention times of 3-62, 4-66, and 6-71 minutes respectively; Fig. 1 ). Calibration curves were constructed from water and plasma which could be superimposed (Fig. 2) were purchased from Fisons Ltd. All other reagents were of analytical grade.
Results
Trough concentrations of ASA fractions in the plasma of patients on uncoated 5-ASA were significantly lower than those seen with the coated product after both seven and 21 days of therapy ( Fig. 3 ; Table   1 ). Urinary excretion, however, (mmol/24 h) was similar in the three groups ( Fig. 3 ; Table 1 ). The excretion of 5-ASA and total ASA in faeces is shown in Table ( mmol/l) and Figure 4 (mmol/24 h). There was a highly significant (28 fold) difference in 5-ASA in patients on the coated compared to the uncoated product (Fig. 4 ) but smaller differences were observed for total ASA because acetyl 5-ASA concentrations were similar in each of the study groups ( Table 1 ). The 21 day faecal dialysate concentration and faecal excretion of 5-ASA and total ASA were significantly lower than seven day values (p<0-05; Fig. 4 ). Plasma concentrations, urine and faecal excretion of total 5-ASA for patients with active and inactive colitis on coated 5-ASA tablets are shown in Table 2 . Although in patients with active disease there were substantial differences between seven and 21 day values, and seven day faecal values in patients with inactive disease, these were not significant probably because of the small numbers in each subgroup. The raised seven day faecal excretion in patients with active disease, however, had fallen to a value comparable with that seen in inactive patients after 21 days of therapy. Ninety per cent of the 5-ASA consumed (10.5 mmol) was excreted in faeces (as total ASA) after seven days of treatment in patients with active colitis compared with 40% for patients with inactive colitis. This difference was not significant. Sixty five per cent of the ingested dose appeared in the stools of the patients treated with coated 5-ASA compared with only 16% in those receiving the uncoated product ( Fig. 4 ; p<0(01).
Discussion
These results confirm that the pH dependent polymer coating of 5-ASA is a highly successful method for delivering total ASA (5-ASA and the metabolite stool, nausea, and skin rash) was seen in 33% of those treated. It may be that the azo-bond itself is responsible for many of the side effects. Acrylic resin coating of 5-ASA in a preparation such as used in this study, which has been shown to release 5-ASA in the ileum and caecum at pH 7 or above,6 provides a valuable and potentially less toxic alternative'9 no adverse effects being encountered in the present study.
In conclusion, 5-ASA coating with methacrylic acid copolymer B (Eudragit S) provides a valuable means of promoting delivery of the drug to its colonic site of action. It may be that polymer coated 5-ASA is better tolerated than traditional and modern azobond molecules, although further comparative trials of both patient acceptability and therapeutic efficacy are required.
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